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Introduction: The largest randomized controlled trial that compared the efﬁcacy of carotid endarterectomy (CEA) with
carotid artery stenting (CAS) showed equivalent outcomes for the composite end point of postoperative stroke,
myocardial infarction (MI), or death. However, CAS had a higher risk of postoperative stroke, and CEA had a higher risk
of MI. We hypothesize that there is a differential association of postoperative stroke, compared with that of postoperative
MI, with reduced long-term survival after carotid revascularization when compared with neither complication.
Methods: The Vascular Study Group of New England database was used to identify all CEA and CAS procedures per-
formed between 2003 and 2011. Patients were stratiﬁed according to whether they experienced an in-hospital post-
operative stroke (minor or major), MI (troponin elevation, electrocardiographic changes, or clinical symptoms), or
neither. Primary study end point was survival during the ﬁrst year and the ﬁrst 5 years postoperatively. Multivariable Cox
proportional hazards models compared the magnitude of association of stroke and MI on survival.
Results: Of 8315 patients, 81 (0.97%) experienced postoperative MI, and 63 (0.76%) experienced stroke. During the ﬁrst
year after operation, survival signiﬁcantly differed among the three groups: neither, 96%; MI, 84%; stroke, 77% (log-rank
P < .0001). After adjusting for confounders, survival after postoperative stroke (hazard ratio [HR], 6.6; 95% conﬁdence
interval [CI], 3.7-12; P < .0001) was nearly twofold less than that after postoperative MI (HR, 3.6; 95% CI, 2-6.8;
P < .0001). During the ﬁrst 5 years postoperatively, multivariable modeling showed postoperative stroke and post-
operative MI remained independent predictors of decreased survival, but the magnitude of association was similar (HR,
2.7; 95% CI, 1.7-4.3 [P < .0001] vs HR, 2.8; 95% CI, 1.8-4.3 [P < .0001]).
Conclusions: During the ﬁrst year after operation, postoperative stroke conferred a twofold lower survival than that after
postoperative MI. By 5 years after operation, these survival curves converged, and the survival disadvantage associated
with stroke became similar to that of MI. These data suggest that different postoperative complications after carotid
revascularization have different implications for patients, with decreased short-term survival in patients experiencing
a postoperative stroke. These ﬁndings help to inform our interpretation of studies that have used a composite end point in
order to evaluate the comparative effectiveness of revascularization strategies. (J Vasc Surg 2013;57:1581-8.)The optimal treatment modality for carotid artery
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trials failed to demonstrate noninferiority of CAS for the
composite end point of stroke and death. The Carotid
Revascularization Endarterectomy vs Stent Trial (CREST)
trial reported no signiﬁcant difference for the composite
end point of postoperative stroke, myocardial infarction
(MI), or death.3 However, subgroup analyses of individual
end points in CREST demonstrated a higher risk of stroke
after CAS, and conversely, a higher risk of MI after CEA.
Despite the conﬂicting results among the trials, these
studies had a decisive effect on practice patterns at the
national level, as evidenced by a doubling of use of CAS
in 2005 after the Stenting and Angioplasty with Protection
in Patients at High Risk for Endarterectomy (SAPPHIRE)
trial, and then in 2007, decreased use of CAS after the
publication of EVA-3S and SPACE.8-10 At the national
level, this demonstrates a willingness by practitioners to
change in response to evidence but also a lack of consensus
on what that evidence suggests.
Some of these conﬂicting results likely arise from the
use of composite primary end points. Efforts to tease out
differences in outcomes have relied on subgroup analyses,1581
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tial for biases of multiple testing.
In this context, the relative effect of a postoperative MI
compared with that of a postoperative stroke on long-term
survival becomes critical to the interpretation of studies
evaluating the comparative effectiveness of alternative
carotid revascularization strategies. We hypothesize that
there is a differential association of postoperative stroke,
compared with postoperative MI, on long-term survival
after carotid revascularization.
METHODS
Study design. Prospectively collected data from the
Vascular Study Group of New England (VSGNE) database
was retrospectively reviewed to identify all patients who
underwent CAS or CEA between January 1, 2003, and
December 31, 2011; the unit of analysis was the index
carotid revascularization. The VSGNE is a regional cooper-
ative quality-improvement initiative, developed in 2002, to
prospectively evaluate outcomes in patients undergoing
vascular surgical procedures. It consists of 140 physicians
from 25 academic and community medical centers across
New England.
Carotid revascularization was performed by a surgeon,
or in the case of CAS, an interventionalist, and eight such
interventionalists contributed data to this cohort. Details
of this registry have been published previously11 and are
available online (www.vsgne.org). Data are physician-
reported at the time of operation and include preoperative,
intraoperative, and in-hospital postoperative details.
Follow-up data are entered at w1 year postoperatively.
All information is sent to a central data repository where
it is aggregated and audited. Trained nurses or clinical
data abstractors enter data; research analysts are blinded
to patient, surgeon, and hospital identity. Since the incep-
tion of the database, a claims-based audit system has been
used to ensure >95% capture of consecutive operations
performed at each center.
Study exclusion criteria included patients who under-
went combined CEA and coronary artery bypass grafting
(CABG), patients who experienced a postoperative MI
and a postoperative stroke, and patients who were missing
postoperative MI or stroke data. Although patients who
experienced a postoperative MI and a postoperative stroke
could be considered to contribute information about peri-
operative morbidity, we excluded them from all analyses to
maintain one uniform cohort of patients for all analyses; in
addition, they represented <1% of patients identiﬁed for
study (7 of 8322), and therefore were unlikely to inﬂuence
the ﬁndings in a meaningful way.
Primary end point and exposure variable. The
primary study end point was survival, assessed over the ﬁrst
year and over the ﬁrst 5 years postoperatively. Survival
was determined by matching patients in the registry with
the Social Security Death Index. Other associations, such
as the effect of symptom status on occurrence of a postoper-
ative complication, were not assessed in the present study.
The primary exposure variable was major postoperativecomplication, deﬁned as in-hospital postoperative MI,
stroke, or neither; data on 30-day postoperative complica-
tions are not available within the data set. Postoperative
MI was deﬁned as any or all of (1) a troponin elevation
beyond the normal upper limit, as deﬁned by the testing
laboratory, without electrocardiographic (ECG) changes, or
(2) clinical symptoms (severe chest pain or radiotherapy
to the left arm or jaw), or (3) ECG changes consistent with
MI, as deﬁned at each participating institution.
Although recognizing that this broadly inclusive deﬁni-
tion is not consistent with the American Heart Association
(AHA) universal deﬁnition of MI,12 we deﬁned MI in this
way to be consistent with the deﬁnition used in several
previous carotid revascularization trials.2,3 In addition,
a literal interpretation of the second part leaves open the
possibility that patients who experienced clinical symptoms
alone would be categorized as having sustained an MI.
Because most practitioners would likely not consider this
sufﬁcient evidence to make that diagnosis, we have
assumed that there would be very few instances of this
misclassiﬁcation when reporting outcomes also. We instead
suspect that most often, this variable is understood to mean
clinical symptoms in addition to troponin elevation,
because the other levels of this nominal variable are “no
MI,” or “troponin elevation only.”
It is a limitation of the data set that we are unable to
assess the number of patients for whom troponin assays
were sent, but were not elevated, or conversely, the number
of patients who experienced ECG evidence of MI with clin-
ical symptoms but did not have troponin assays sent; those
patients in the ﬁrst scenario would likely be counted as
having “no MI,” whereas those in the second scenario
would be counted as having sustained an MI.
Postoperative stroke included major and minor strokes,
occurring in the ipsilateral or contralateral hemisphere;
transient ischemic attacks were not included. The occur-
rence of a postoperative stroke was at the determination
of the physician; the data set does not capture information
such as radiographic evidence of stroke or involvement of
a neurologist or other consultant.
Secondary end point. We assessed mortality within
the ﬁrst 30 days postoperatively, stratiﬁed according to
the occurrence of postoperative stroke, postoperative MI,
or neither, in order to better understand the associations
of these with early death. We did not exclude these patients
from our overall analyses of survival because we felt they
still contributed valuable information regarding the risk
of death after a particular exposure.
Covariates examined. Patient information was
collected for >100 clinical and demographic variables
(available at www.vsgne.org). Demographic information
included age at the time of the procedure, sex, and race.
Comorbidities examined included coronary artery disease
(CAD, categorized as history of MI without current
symptoms or stable angina, or unstable angina or MI
within the past 6 months), chronic obstructive pulmonary
disease (dependent on medication or home oxygen),
congestive heart failure (CHF, by history), diabetes
Table I. Demographics for patients in the Vascular Study Group of New England cohort 2003-2011, stratiﬁed according
















<60 1260 (15.2) 1242 (15.2) 7 (8.6) 11 (17.5)
60-69 2693 (32.4) 2647 (32.4) 34 (42) 12 (19.1)
70-79 3088 (37.1) 3035 (37.1) 29 (35.8) 24 (38.1)
>80 1274 (15.3) 1247 (15.3) 11 (13.6) 16 (25.4)
Male sex 5000 (60.1) 4924 (60.3) 38 (46.9) 38 (60.3) .05
White race 8180 (98.4) 8039 (98.4) 80 (98.8) 61 (96.8) .6
Preoperative factors
Smoking status .63
Never 1676 (20.2) 1651 (20.2) 13 (16.1) 12 (19.1)
Former/current 6628 (79.8) 6509 (79.8) 68 (84) 51 (81)
COPD <.0001
None/not treated 7179 (86.4) 7063 (86.5) 63 (77.8) 53 (84)
Medications 994 (12) 974 (12) 10 (12.4) 10 (15.9)
Home oxygen 141 (1.7) 133 (1.6) 8 (9.9) 0 (0)
CAD .02
None 5607 (67.5) 5520 (67.6) 42 (51.9) 45 (71.4)
History of MI/stable angina 2540 (30.6) 2488 (30.5) 35 (43.2) 17 (27)
Unstable angina; MI #6 months 165 (2) 160 (2) 4 (5) 1 (1.6)
Congestive heart failure 700 (8.4) 677 (8.3) 17 (21) 6 (9.5) .0002
Hypertension 7288 (87.7) 7154 (87.6) 74 (91.4) 60 (95.2) .11
Diabetes mellitus 2601 (31.3) 2540 (31.1) 39 (48.2) 22 (34.9) .004
Renal function .05
Creatinine #1.8 mg/dL 7596 (94.1) 7469 (94.2) 69 (87.3) 58 (95.1)
Creatinine >1.8 mg/dL 429 (5.3) 416 (5.3) 10 (12.7) 3 (4.9)
Dialysis-dependent 45 (0.6) 45 (0.6) 0 (0) 0 (0)
Contralateral ICA stenosis .41
<50% 4350 (52.4) 4281 (52.4) 38 (46.9) 31 (49.2)
50%-69% 1752 (21.1) 1723 (21.1) 20 (24.7) 9 (14.3)
70%-80% 832 (10) 819 (10) 8 (9.9) 5 (7.9)
>80% 521 (6.3) 508 (6.2) 7 (8.6) 6 (9.5)
Occluded 571 (6.9) 558 (6.8) 6 (7.4) 7 (11.1)
Unknown 281 (3.4) 274 (3.4) 2 (2.5) 5 (7.9)
Preoperative medications
Antiplatelet agents 7498 (90.2) 7368 (90.2) 75 (92.6) 55 (87.3) .57
b-blockers 6492 (78.1) 6373 (78) 69 (85.2) 50 (79.4) .29
Statins 6359 (76.5) 6244 (76.4) 67 (82.7) 48 (76.2) .61
Operative factors
General anesthesia 6903 (83) 6782 (83) 71 (87.7) 50 (79.4) .4
Heparin 8250 (99.2) 8108 (99.3) 79 (97.5) 63 (100) .16
Protamine 4173 (50.2) 4093 (50.1) 45 (55.6) 35 (55.6) .43
Procedure type .002
CAS 481 (5.8) 468 (5.7) 3 (3.7) 10 (15.9)
CEA 7834 (94.2) 7703 (94.3) 78 (96.3) 53 (84.1)
Symptomatic 2933 (35.3) 2865 (35.1) 33 (40.7) 35 (55.5) .002
CAD, Coronary artery disease; CAS, carotid artery stenting; CEA, carotid endarterectomy; COPD, chronic obstructive pulmonary disease; ICA, internal
carotid artery.
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tion or diet, or both), hypertension (history of hyperten-
sion or blood pressure $140/90 mm Hg on the
preoperative evaluation), and history of tobacco use. Renal
disease was categorized in three strata: normal (serum
creatinine #1.8 mg/dL), renal insufﬁciency (serum creati-
nine >1.8 mg/dL), and dialysis-dependence. Results of
preoperative stress testing were deﬁned as not performed,
negative for ischemia, or positive for ischemia, MI, or both.
History of previous coronary revascularization includedCABG and percutaneous coronary intervention. Contra-
lateral internal carotid artery stenosis was classiﬁed
as <50%, 50% to 69%, 70% to 79%, $80%, occluded, or
unknown.
Preoperative medication use was recorded, including b-
blockers, antiplatelet agents (aspirin, clopidogrel, or both),
and statins. Anesthetic technique was categorized as
general or other, which included local or regional anes-
thetic. Other operative information included the use of
heparin and the use of protamine for reversal. Patients










Total cohort 8171 (98.3) 81 (.97) 63 (.76)
CEA 7703 (98.3) 78 (1.0) 53 (.68)
CAS 468 (97.3) 3 (.62) 10 (2.1)
CAS, Carotid artery stenting; CEA, carotid endarterectomy;MI, myocardial
infarction.
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stenosis if there was any history of ipsilateral ocular symp-
toms or cortical transient ischemic attack or stroke,
including major and minor strokes. Hospital site was also
recorded.
Statistical analysis. Descriptive statistics were used to
assess incidence of postoperative MI and stroke. Univariate
analyses were conducted with c2 analysis for nominal vari-
ables; this included postoperative complication, demo-
graphics, comorbid conditions, contralateral ICA stenosis,
preoperative medications, and operative factors including
hospital site. Survival analyses were performed according
to the Kaplan-Meier method, with intergroup compari-
sons made using log-rank testing. Analyses were performed
on the entire cohort, with additional subgroup analyses
based on procedure type. However, we intentionally
limited our use of subgroup analyses because this study was
neither designed nor properly powered to assess differences
in revascularization strategies. Nolan et al13 recently con-
ducted a study using VSGNE data that was designed
speciﬁcally to compare CAS with CEA.
Cox proportional hazards modeling with backward
stepwise selection was used to determine the magnitude
of association of postoperative MI and stroke with the
risk of death during the ﬁrst year and 5 years postopera-
tively. Covariates were chosen based on a univariate screen
with entry for those with P < .2. Signiﬁcance was accepted
at the P < .05 level. All analyses were conducted using SAS
9.2 software (SAS Institute, Cary, NC).RESULTS
Cohort characteristics. Between January 2003 and
December 2011, 8991 patients underwent carotid revascu-
larization procedures recorded in the VSGNE database.
We excluded 464 patients because data were missing for
the exposure variable, postoperative stroke, or postopera-
tive MI. Also excluded were 205 patients who underwent
combined CEA and CABG and a further seven patients
who experienced postoperative MI and stroke, leaving
8315 patients for analysis (Table I). CEA was performed
in 7834 (94%) and CAS in 481 (6%). Most patients were
men (5000 [61%]), aged between 60 and 79 years (5781
[70%]), with a history of tobacco use (6628 [80%]), CAD
(2705 [32.6%], and hypertension (7288 [87.7%]). Proce-
dures were performed for symptomatic lesions in 2933
(35.3%). High-grade stenoses (>70%) or occlusions of the
contralateral ICA were present in 1924 patients (23.2%).
General anesthesia was used for 6903 procedures (83%).
Postoperative MI, stroke, and long-term survival.
More patients experienced postoperative MI (81 [0.97%])
than those who experienced postoperative stroke
(63 [0.76%]; Table II). On univariate analysis, the inci-
dence of postoperative MI or stroke was 133 (1.7%) in
those undergoing CEA, which was signiﬁcantly lower than
the 13 incidence (2.7%) in CAS patients (P ¼ .002). On
analysis of each end point separately, a greater number of
MIs occurred after CEA (78 [1.0%]) than after CAS(3 [0.62%]), whereas a greater number of strokes occurred
after CAS (10 [2.1%]) than after CEA (53 [0.68%]).
During the ﬁrst year, Kaplan-Meier survival analysis
revealed a signiﬁcant difference when the cohort was strat-
iﬁed according to occurrence of postoperative MI, stroke,
or neither (Fig 1). Among those without MI or stroke,
the 1-year survival was 96% (standard error [SE], 0.22%),
whereas survival was 84% (SE, 4.1%) among those with
a postoperative MI and 77% (SE, 5.5%) among those
with a postoperative stroke.
During the ﬁrst 5 years, Kaplan-Meier survival analysis
revealed a signiﬁcant difference when the cohort was strat-
iﬁed according to occurrence of postoperative MI, stroke,
or neither (Fig 2). However, a convergence of the
Kaplan-Meier curves occurred at the 5-year point, with
similar survival between the postoperative MI group and
the postoperative stroke group. The 5-year survival was
80% (SE, 0.62%) among those without MI or stroke,
56% (SE, 7.8%) among those with a postoperative MI,
and 60% (SE 7.4) for those with postoperative stroke.
Thirty-day mortality. Life-table analysis revealed that
the 30-day mortality among patients without MI or stroke
was 0.5% (SE, 0.07%). Thirty-day mortality was 8.7% (SE,
3.2%) among those with postoperative MI and 12.8% (SE,
4.2) among those with postoperative stroke.
Independent predictors of 1-year survival. On
multivariable analysis, postoperative MI and stroke were
both predictors of worse survival during the ﬁrst 1 year.
Survival during the ﬁrst year (hazard ratio [HR], 3.6;
95% conﬁdence interval [CI], 2.0-6.8; P < .0001) for
those with postoperative MI was signiﬁcantly less than for
those who did not experience a postoperative complication
(Table III). Similarly, survival during the ﬁrst year was
signiﬁcantly (HR, 6.6; 95% CI, 3.7-11.9, P < .0001)
less for those with postoperative stroke than for those
who did not experience a postoperative complication
(Table III).
Independent predictors of 5-year survival. Multivar-
iable analysis of survival during the ﬁrst 5 years postopera-
tively showed that postoperative MI and stroke were
signiﬁcant predictors of worse survival. Survival during
the ﬁrst 5 years (HR, 2.8; 95% CI, 1.8-4.3; P < .0001)
was signiﬁcantly less for those with postoperative MI than
for those who did not experience a postoperative complica-
tion (Table IV). Postoperative stroke was also associated
Fig 1. Kaplan-Meier (K-M) curves of survival over the ﬁrst year postoperatively, stratiﬁed according to postoperative
myocardial infarction (MI), stroke, or neither.
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95% CI, 1.7-4.3; P < .0001) compared with those who did
not experience a postoperative complication.
DISCUSSION
This study demonstrates that patients experiencing an
MI or a stroke after carotid revascularization have signiﬁ-
cant reductions in survival over the ﬁrst 1 and 5 years
compared with patients experiencing neither complication.
However, postoperative MI and stroke have different
implications. During the ﬁrst year, postoperative stroke
conferred nearly twice the hazard of reduced survival as
MI (HR, 6.6 vs 3.6). By 5 years, the magnitude of associ-
ation of these two postoperative complications was similar,
with both conferring a nearly threefold reduction in
survival compared with patients experiencing neither
complication (stroke: HR, 2.7; MI: HR, 2.8). Other
predictors of reduced long-term survival included advanced
age, chronic obstructive pulmonary disease, CHF, diabetes
mellitus, impaired renal function, and higher degrees of
contralateral ICA stenosis.
Despite postoperative MI demonstrating a signiﬁcant
association with decreased survival, history of CAD was
not signiﬁcant in the 1-year or 5-year models. Although
this seems somewhat counterintuitive, it may be that
CAD, as manifested by ischemic symptoms, is not associ-
ated with reduced survival, but rather that CAD associated
with CHF is, because CHF is a signiﬁcant independent
predictor in both models. This may reﬂect the degree to
which cardiac function has been affected as the mediator
of reduced survival.Several studies have characterized outcomes after CEA
and CAS, although most have used composite end points.
This has partly contributed to the controversy surrounding
determination of the optimal revascularization strategy.
Wang et al14 evaluated predictors of 1-year outcomes,
focusing primarily on the effect of each procedure type,
CEA vs CAS, on survival. However, they did not speciﬁ-
cally evaluate the effect on survival of a postoperative MI
or stroke after carotid revascularization. The SAPPHIRE
trial assessed outcomes among patients at high risk for
CEA due to medical comorbidities and found noninferior-
ity of CAS for the composite end point of perioperative MI,
stroke, and death.2 The SPACE trial evaluated outcomes
for CAS and CEA among patients with symptomatic
carotid stenosis7 and concluded that CAS was inferior to
CEA for the composite end point of stroke and death.
The difference in conclusions may have related to a differ-
ence in end points.
Two of the largest trials to date included subgroup
analyses of single end points. The International Carotid
Stenting Study evaluated outcomes of CEA and CAS for
symptomatic carotid stenosis and found a higher risk of
stroke at 30 days associated with CAS.5 The CREST trial
included symptomatic and asymptomatic carotid stenosis,
and no signiﬁcant difference was found between the two
revascularization strategies for a composite end point of
stroke, MI, and death.3 However, subgroup analysis
revealed higher risk of stroke associated with CAS and
higher risk of MI with CEA.
The technique of meta-analysis has also been used in an
attempt to clarify these conﬂicting results and multiple
Fig 2. Kaplan-Meier (K-M) curves of survival over the ﬁrst 5 years postoperatively, stratiﬁed according to postoperative
myocardial infarction (MI), stroke, or neither.
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their meta-analysis, Wang et al found that in the perioper-
ative period, similar to the ﬁndings of the CREST trial,
CEA was associated with higher rates of MI, whereas
CAS was associated with higher rates of stroke. This
provided good statistical evidence that the two revascular-
ization strategies have different likelihoods of these two
complications being associated with them. Therefore, the
next step in interpretation of these studies requires an anal-
ysis of the relative effect of these complications on other
outcomes such as long-term survival.
Our primary analysis was a characterization of the effect
of postoperative MI and stroke on 1-year and 5-year
survival after carotid revascularization. The utility of evalu-
ating these two exposures separately was further supported
by a secondary substudy in the CREST trial that evaluated
health-related quality of life (HRQOL).16 They reported
the effect of revascularization type on HRQOL and found
few differences between CAS and CEA by 1 year.
However, subgroup analyses showed the occurrence of
a postoperative stroke was associated with worse HRQOL
for seven of eight health-status domains. In contrast, those
who experienced a postoperative MI reported only a worse
general health perception at 1 year, but no other signiﬁcant
differences in HRQOL. The authors concluded that these
complications had different implications for HRQOL,
whereas procedure type made little difference by 1 year
postoperatively.
The aforementioned studies evaluated patient
outcomes according to revascularization strategy, but the
effect of individual adverse outcomes (MI or stroke) was
not addressed or was assessed only as a post hoc subgroupanalysis and was therefore subject to signiﬁcant inherent
limitations. In contrast, our primary analysis focused specif-
ically on the effect of these serious postoperative events.
Our ﬁndings build on the ﬁndings from the CREST
HRQOL study that suggested that postoperative stroke
and MI have different implications for patients after carotid
revascularization. The occurrence of a postoperative MI, or
a postoperative stroke, portended a worse early survival
prognosis, with stroke affecting 1-year survival far more
than MI.
It is also important to note that the association we have
identiﬁed does not demonstrate cause and effect. For
instance, a postoperative MI may occur more commonly
in a patient with more severe underlying CAD that would
lead to reduced survival. Conversely, a postoperative MI
may lead to worsening cardiac function, with a subsequent
decline in overall health that leads to reduced survival
compared with a patient who did not experience a postop-
erative MI. Our analyses do not allow for interpretation of
the direction of the association, only that there is an asso-
ciation of postoperative stroke and postoperative MI with
an increased hazard of death at 1 and 5 years postopera-
tively compared with having neither of these postoperative
complications.
The event rate in this study is lower than that reported
in many other studies. For example, the CREST investiga-
tors reported an incidence of 6.4% for stroke and 3.4% for
MI in the periprocedural period,3 which is substantially
higher than the rates observed in the VSGNE cohort.
This may represent a limitation of self-reporting in
VSGNE. In an attempt to reduce this type of potential
bias, VSGNE has validated the occurrence of postoperative
Table III. Cox proportional hazards model of survival
over the ﬁrst year postoperatively
Covariate HR (95% CI) P
Postoperative complication
No stroke or MI Referent
MI 3.6 (2.0-6.8) <.0001
Stroke 6.6 (3.7-11.9) <.0001
Age, years
<60 Referent
60-69 0.81 (0.51-1.3) .4
70-79 1.6 (1.1-2.5) .02
>80 3.2 (2.1-4.9) <.0001
COPD
None/not treated Referent
Medications 1.1 (0.78-1.6) .57
Home oxygen 3.8 (2.4-6.0) <.0001
CAD
None Referent
History of MI or stable angina 1.1 (0.79-1.4) .72
Unstable angina or MI #6 months 1.4 (0.69-3.0) .33
Previous coronary revascularization 1.1 (0.80-1.4) .67
Congestive heart failure 1.7 (1.3-2.4) .001
Diabetes mellitus 1.4 (1.1-1.7) .01
Renal function
Creatinine #1.8 mg/dL Referent
Creatinine >1.8 mg/dL 1.7 (1.2-2.5) .004
Dialysis-dependent 6.1 (3.4-11) <.0001
Contralateral ICA stenosis
<50% Referent
50%-69% 1.0 (0.74-1.4) .89
70%-80% 1.5 (1.0-2.1) .04
>80% 2.2 (1.5-3.2) <.0001
Occluded 1.3 (0.82-2.1) .26
Unknown 1.6 (0.91-2.9) .1
Preoperative b-blocker use 0.89 (0.67-1.2) .42
Preoperative statin use 0.81 (0.62-1.0) .1
General anesthesia 0.75 (0.56-1.0) .05
CAD, Coronary artery disease; CI, conﬁdence interval; COPD, chronic
obstructive pulmonary disease; HR, hazard ratio; ICA, internal carotid
artery; MI, myocardial infarction.
Table IV. Cox proportional hazards model of survival
over the ﬁrst 5 years postoperatively
Covariate HR (95% CI) P
Postoperative complication
No stroke or MI Referent
MI 2.8 (1.8-4.3) <.0001
Stroke 2.7 (1.7-4.3) <.0001
Age, years
<60 Referent
60-69 1.1 (.86-1.4) .44
70-79 2.1 (1.6-2.6) <.0001
>80 4.5 (3.5-5.8) <.0001
Smoking status, never 0.65 (.54-.77) <.0001
COPD
None/not treated Referent
Medications 1.5 (1.3-1.8) <.0001
Home oxygen 3.3 (2.5-4.5) <.0001
CAD
None Referent
History of MI or stable angina 1.2 (.99-1.4) .06
Unstable angina or MI #6 months .97 (.58-1.6) .89
Previous coronary revascularization 0.99 (.85-1.2) .87
Stress testing
Not performed 1.0 (.88-1.2) .72
Normal Referent
Ischemia/MI/both 1.2 (.96-1.5) .12
Congestive heart failure 1.7 (1.4-2.1) <.0001
Hypertension .89 (.73-1.1) .25
Diabetes mellitus 1.4 (1.2-1.6) <.0001
Renal function
Creatinine #1.8 mg/dL Referent
Creatinine >1.8 mg/dL 1.6 (1.3-1.9) <.0001
Dialysis-dependent 5.3 (3.5-7.9) <.0001
Contralateral ICA stenosis
<50% Referent
50%-69% 1.1 (.96-1.3) .15
70%-80% 1.3 (1.1-1.6) .008
>80% 1.6 (1.3-2.1) <.0001
Occluded 1.6 (1.3-2.1) <.0001
Unknown 1.4 (1.0-2.0) .04
Preoperative antiplatelet use 1.0 (.83-1.2) .95
Preoperative statin use .80 (.70-.92) .002
General anesthesia .77 (.66-.91) .002
CAD, Coronary artery disease; CI, conﬁdence interval; COPD, chronic
obstructive pulmonary disease; HR, hazard ratio; ICA, internal carotid
artery; MI, myocardial infarction.
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edition codes for this complication on hospital administra-
tive claims for CEA.
A recent publication from Nolan et al13 detailed this
method. They found that that 8% of CEA performed
according to administrative claims had not been entered
into the VSGNE. On review of administrative claims that
included a code for postoperative iatrogenic stroke, 100%
of these had been entered properly into the VSGNE; that
is, none of the cases that had been identiﬁed as missing
from VSGNE contained a code for postoperative stroke.
Furthermore, the VSGNE does not mandate an indepen-
dent neurologic examination before and after the proce-
dure, as is often the case in carotid revascularization
trials. As with all self-reported databases, the reliance on
the physician who performed the revascularization to
report the occurrence of a postoperative stroke does leave
open the possibility of an under-reporting bias. Although
it would be preferable to mandate independent postopera-
tive neurologic evaluations for all patients after carotid
revascularization, this is not feasible within the VSGNE.As mentioned previously, the deﬁnition used for MI
does not conform to the AHA universal deﬁnition of
MI12; instead, it includes isolated troponin elevations.
This decision was made deliberately to be consistent with
the deﬁnition used in several previous carotid revasculariza-
tion trials. Our deﬁnition varies from the AHA universal
deﬁnition by not requiring other clinical markers of
ischemia such as chest pain or ECG changes. Given the
way the variable is deﬁned in the data set, this means that
patients who had a troponin elevation without necessarily
demonstrating ECG changes or chest pain would be
included as having sustained this postoperative complica-
tion. Because of the limitations of the data set, we are
not able to determine the number of patients for whom
troponin assays were sent, but not elevated. The likely
effect of using this more inclusive MI deﬁnition would be
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patients who experienced a less severe cardiac event.
Accordingly, the association of MI with reduced survival
might have been more pronounced if we had adhered
strictly to this AHA deﬁnition. A corollary to this is the
recognition that there may be an association of isolated
postoperative troponin elevations that fall short of the
criteria for MI with decreased survival.
It is important to state explicitly that the purpose of
this investigation was not to compare the effectiveness of
CEA and CAS. In contrast, this study was designed to
speciﬁcally assess the association of a postoperative MI or
a postoperative stroke with reduced long-term survival,
compared with neither complication, after carotid revascu-
larization. As a result, these data do not allow us to make
conclusions regarding the optimal carotid revascularization
strategy. Other VSGNE investigators have addressed the
comparative effectiveness question between CEA and
CAS.13
CONCLUSIONS
Postoperative stroke and postoperative MI affect
patients differently, with stroke being signiﬁcantly associ-
ated with more early death than MI. This analysis informs
the interpretation of the various studies that have used
a composite end point of stroke, MI, and death. It also
highlights the need for future studies of the comparative
effectiveness of CEA and CAS to evaluate postoperative
stroke and postoperative MI separately because they have
different implications for HRQOL and survival.
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